NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT05567679 2023-09-22
A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer
Cedars-Sinai Medical Center
Phase EARLY_PHASE1 Withdrawn
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT05604417 2023-07-07
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Massachusetts General Hospital
Phase 1/2 Withdrawn
NCT05152459 2023-05-31
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT03217253 2020-02-07
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn